Rumler H, Schmithals C, Werner C, Bollacke A, Aichele D, Gotz C
ACS Pharmacol Transl Sci. 2024; 7(12):3846-3866.
PMID: 39698287
PMC: 11651316.
DOI: 10.1021/acsptsci.4c00426.
da Silva Zanzarini I, Henrique Kita D, Scheiffer G, Karoline Dos Santos K, de Paula Dutra J, Augusto Pastore M
Bioorg Chem. 2024; 146:107283.
PMID: 38513324
PMC: 11069345.
DOI: 10.1016/j.bioorg.2024.107283.
Damiani D, Tiribelli M
Biomedicines. 2024; 12(1).
PMID: 38255216
PMC: 10813371.
DOI: 10.3390/biomedicines12010111.
Papp B, Le Borgne M, Perret F, Marminon C, Jozsa L, Peto A
Pharmaceutics. 2023; 15(12).
PMID: 38140042
PMC: 10748227.
DOI: 10.3390/pharmaceutics15122701.
Nasuhipur F, Ghasemi Z, Poupon M, Dusek M
RSC Adv. 2023; 13(26):17812-17816.
PMID: 37323449
PMC: 10261912.
DOI: 10.1039/d3ra02515b.
In Silico Identification and In Vitro Evaluation of New ABCG2 Transporter Inhibitors as Potential Anticancer Agents.
Di Micco S, Di Sarno V, Rossi M, Vestuto V, Konno T, Novi S
Int J Mol Sci. 2023; 24(1).
PMID: 36614168
PMC: 9820944.
DOI: 10.3390/ijms24010725.
Recent Advancements in the Development of Anti-Breast Cancer Synthetic Small Molecules.
Elkaeed E, Abd El Salam H, Sabt A, Al-Ansary G, Eldehna W
Molecules. 2021; 26(24).
PMID: 34946704
PMC: 8709016.
DOI: 10.3390/molecules26247611.
4,5,7-Trisubstituted indeno[1,2-b]indole inhibits CK2 activity in tumor cells equivalent to CX-4945 and shows strong anti-migratory effects.
Birus R, El-Awaad E, Ballentin L, Alchab F, Aichele D, Ettouati L
FEBS Open Bio. 2021; 12(2):394-411.
PMID: 34873879
PMC: 8804612.
DOI: 10.1002/2211-5463.13346.
4,5,6,7-Tetrahydroindol-4-Ones as a Valuable Starting Point for the Synthesis of Polyheterocyclic Structures.
Horsten T, Dehaen W
Molecules. 2021; 26(15).
PMID: 34361747
PMC: 8348459.
DOI: 10.3390/molecules26154596.
Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-]indole Derivative, Discovered as CK2 Inhibitor.
El-Awaad E, Birus R, Marminon C, Bouaziz Z, Ballentin L, Aichele D
Pharmaceuticals (Basel). 2021; 14(6).
PMID: 34198928
PMC: 8226678.
DOI: 10.3390/ph14060542.
Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.
Henrique Kita D, Guragossian N, Fatima Zattoni I, Rotuno Moure V, Gomes de Moraes Rego F, Lusvarghi S
Sci Rep. 2021; 11(1):1788.
PMID: 33469044
PMC: 7815716.
DOI: 10.1038/s41598-020-79892-w.
ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning.
Jiang D, Lei T, Wang Z, Shen C, Cao D, Hou T
J Cheminform. 2021; 12(1):16.
PMID: 33430990
PMC: 7059329.
DOI: 10.1186/s13321-020-00421-y.
QSAR Model of Indeno[1,2-]indole Derivatives and Identification of -isopentyl-2-methyl-4,9-dioxo-4,9-Dihydronaphtho[2,3-]furan-3-carboxamide as a Potent CK2 Inhibitor.
Haidar S, Marminon C, Aichele D, Nacereddine A, Zeinyeh W, Bouzina A
Molecules. 2020; 25(1).
PMID: 31888043
PMC: 6982966.
DOI: 10.3390/molecules25010097.
Diacritic Binding of an Indenoindole Inhibitor by CK2α Paralogs Explored by a Reliable Path to Atomic Resolution CK2α' Structures.
Lindenblatt D, Nickelsen A, Applegate V, Hochscherf J, Witulski B, Bouaziz Z
ACS Omega. 2019; 4(3):5471-5478.
PMID: 31559376
PMC: 6756786.
DOI: 10.1021/acsomega.8b03415.
Role of protein kinase CK2 in antitumor drug resistance.
Borgo C, Ruzzene M
J Exp Clin Cancer Res. 2019; 38(1):287.
PMID: 31277672
PMC: 6612148.
DOI: 10.1186/s13046-019-1292-y.
In Vitro and in Silico Evaluation of Bikaverin as a Potent Inhibitor of Human Protein Kinase CK2.
Haidar S, Aichele D, Birus R, Hielscher J, Laitinen T, Poso A
Molecules. 2019; 24(7).
PMID: 30965682
PMC: 6479664.
DOI: 10.3390/molecules24071380.
A Simple and Efficient Synthesis of Highly Substituted Indeno[1,2-]pyrrole and Acenaphtho[1,2-]pyrrole Derivatives by Tandem Three-Component Reactions.
Tang X, Zhu S, Ma Y, Wen R, Cen L, Gong P
Molecules. 2018; 23(11).
PMID: 30463337
PMC: 6278260.
DOI: 10.3390/molecules23113031.
Discovery of DEBIC to correlate P-selectin inhibition and DNA intercalation in cancer therapy and complicated thrombosis.
Chen H, Wang W, Zhang X, Liu S, Wang Y, Zhu H
Oncotarget. 2018; 9(63):32119-32133.
PMID: 30181803
PMC: 6114953.
DOI: 10.18632/oncotarget.23151.
Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.
Protopopov M, Ostrynska O, Starosyla S, Vodolazhenko M, Sirko S, Gorobets N
Mol Divers. 2018; 22(4):991-998.
PMID: 29845490
DOI: 10.1007/s11030-018-9836-1.
Inhibition of Shiga toxin-converting bacteriophage development by novel antioxidant compounds.
Bloch S, Nejman-Falenczyk B, Pierzynowska K, Piotrowska E, Wegrzyn A, Marminon C
J Enzyme Inhib Med Chem. 2018; 33(1):639-650.
PMID: 29536772
PMC: 6009899.
DOI: 10.1080/14756366.2018.1444610.